Cure-Coming

259,00 kr.

12 in stock

Cure-Coming

TrainedbyJP Nutrition brings you Cure-Coming, an ultra-absorbable curcumin for whole-body health support containing ultra-potent patented BCM-95® Curcumin, which has been shown to help lower the catabolic effects of exercise, brain/immune/digestive health, and antioxidant support.

Curcumin, the bioactive component of turmeric, Curcuma longa has an unusually broad spectrum of activities, especially its antioxidant  properties.

In short, curcumin has the potential to lower C-reactive protein, induce autophagy through mTOR inhibition (selective destruction of damaged cellular organelles), protect against cardiac hypertrophy..

Despite curcumin’s promising nutritional and pharmacological properties, it exhibits low water solubility, poor gastrointestinal absorption, and poor bioavailability.

Its high rate of metabolism, metabolic inactivation and rapid elimination from the body make it difficult to achieve appreciable plasma concentrations. Due to its poor oral absorption, it is difficult for orally administered curcumin to reach blood levels sufficient to exert its bioactivities. Poor absorption from the gut and rapid metabolism in the body are cited as reasons for the lack of systemic availability.

Combinations with piperine have been most common. Piperine, an inhibitor of phase II hepatic metabolism and intestinal glucuronidation. In rats, the bioavailability of curcumin increased by 154% with piperine compared to a control group without piperine. In humans, piperine (20 mg/kg) was co-administered with curcumin (2 g) and the bioavailability was 20 times greater than the control group. However, increasing bioavailability by inhibiting phase II metabolism must be done carefully, as many compounds are detoxified through this hepatic pathway, which can be slowed by administering piperine.

BCM-95® is a new bio-enhanced preparation of curcumin with the addition of phosphatidylcholine and turmeric essential oils (especially aromatic tumerone volatile oil), which leads to improved and sustained absorption. In a human study, 2 g administration showed that the bioavailability of BCM-95 (based on curcumin Area Under Curve (AUC)) was almost 6.93 times higher than that of a control curcumin formulation without additive. The half-life was found to be approx. 4.96 hours compared to 2.6 hours for the control. 2 g/day dose levels are well tolerated without even mild side effects. However, the mechanisms behind these improvements are unknown.

TrainedbyJP Nutrition stands by this long-standing patented form of BCM-95® curcumin and we are proud to produce Cure-Coming; a supplement that we believe supports the health of almost every organ in your body.

References

Antony, B et al. A pilot cross-over study to evaluate human oral bioavailability of BCM-95®CG (Biocurcumax™), a novel bioenhanced preparation of curcumin. Indian J Pharm Sci. 2008. 70(4): 445–449.

Kurita, T. Novel Curcumin Oral Delivery Systems. Anticancer research. 2013. 33(7): 2807-2821.

Tatti, M et al. BCM-95 and (2-hydroxypropyl)-β-cyclodextrin reverse autophagy dysfunction and deplete stored lipids in Sap C-deficient fibroblasts. Human Molecular Genetics. 2015. 24(15): 4198–4211.

Karawi, D et al. The role of curcumin administration in patients with major depressive disorder: minimeta-analysis of clinical trials. Research in phytotherapy. 2015. 30 (2): 176-183.

Rainey-Smith, SR et al. Curcumin and cognition: a randomized, placebo-controlled, double-blind study in community-dwelling older adults. British Journal of Nutrition. 2016. 115 (12): 2106–2113.

Purpura M et al. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in humans. Eur J Nutr. 2018. 57(3): 929–938.

Hewlings, S et al. Curcumin: A review of its effects on human health. Foodstuffs. 2017. 6(10): 92.

https://examine.com/supplements/curcumin

Per portion

400mg BCM-95® curcumin Tumeric extract

Reviews

There are no reviews yet.

Be the first to review “Cure-Coming”

Select a Pickup Point

Cure-Coming

12 in stock